ImmunityBio, Inc. (NASDAQ: IBRX) has received Expanded Access authorization from the U.S. Food and Drug Administration (FDA) for its Cancer BioShield™ platform, featuring ANKTIVA® (nogapendekin alfa inbakicept-pmln). This authorization allows the treatment of lymphopenia, a life-threatening immune deficiency, in adult patients with refractory or relapsed solid tumors who have progressed after first-line standard therapies such as chemotherapy, radiation, or immunotherapy. This significant regulatory approval provides new hope for patients with solid tumors experiencing immune collapse, offering an innovative approach to cancer care by restoring lymphocyte levels and potentially altering disease progression. The positive survival outcomes observed in metastatic pancreatic cancer patients at the ASCO Annual Meeting 2025 underscore the potential impact of this treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。